| 摘要 |
<p num="1"><br/><br/><br/>The present invention provides a dimeric TCR (dTCR) or single-chain TCR <br/>(scTCR) associated with selected therapeutic agents, wherein said TCR <br/>comprises a first segment constituted by an amino acid sequence corresponding <br/>to a TCR .alpha. chain variable domain sequence fused to the N terminus of an <br/>amino acid sequence corresponding to a TCR .alpha. chain constant domain <br/>extracellular sequence, a second segment constituted by an amino acid sequence <br/>corresponding to a TCR ~ chain variable domain fused to the N terminus of an <br/>amino acid sequence corresponding to TCR ~ chain constant domain extracellular <br/>sequence, a disulfide bond between the first and second chains, said disulfide <br/>bond being one which has no equivalent in native .alpha..beta. T cell <br/>receptors, and in the case of said scTCRs further comprising a linker sequence <br/>linking the C terminus of the first segment to the N terminus of the second <br/>segment, or vice versa, the length of the linker sequence and the position of <br/>the disulfide bond being such that the variable domain sequences of the first <br/>and second segments are mutually orientated substantially as in native <br/>.alpha..beta. T cell receptors.<br/>
|
